Improvements in objective and subjective measures of chronic cough with gefapixant: A pooled Phase 3 efficacy analysis of predefined subgroups

This pooled analysis examined the efficacy of gefapixant versus placebo in predefined subgroups of patients with refractory or unexplained chronic cough enrolled in the Phase 3 COUGH-1 and COUGH-2 trials; data were examined in 1360 subjects, according to sex, geographic region, age, cough duration, cough severity, coughs/hour over 24 hours, and primary diagnosis. In both studies, cough frequency was measured using the Vitalograph VitaloJAK device. Awake cough frequency was assessed by trained Vitalograph cough analysts.